Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VericelVCEL +0.11%83 Days Sales Outstanding is 87.23 as of Jun. 2026, which is 7% below its 10-year median of 93.62. GuruFocus rates VCEL with a GF Score™ of 83/100 and a GF Value™ of $53.77 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 840 Biotechnology companies, Vericel ranks worse than 60.24% on this metric.
Vericel's average Accounts Receivable for the
three
months ended in Jun. 2026 was $74.0 Mil. Vericel's Revenue for the
three
months ended in Jun. 2026 was $77.5 Mil.
Hence, Vericel's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 87.23.
The historical rank and industry rank for Vericel's Days Sales Outstanding or its related term are showing as below:
VCEL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 83.81 Med: 93.62 Max: 100.96
Current: 85.19
During the past 13 years, Vericel's highest Days Sales Outstanding was 100.96. The lowest was 83.81. And the median was 93.62.
VCEL's Days Sales Outstanding is ranked worse than 60.24% of 840
companies
in the Biotechnology industry
Industry Median: 69.09
vs VCEL: 85.19
Vericel's Days Sales Outstanding
increased
from Jun. 2025 (84.55) to Jun. 2026 (87.23).
Vericel (NAS:VCEL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Vericel Days Sales Outstanding Related Terms
Vericel Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Vericel's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCEL vs KLRA, MLYS, NUVB: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Vericel's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Vericel's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (VCEL) has a Days Sales Outstanding of 87.23 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vericel and its competitors. This is near median its historical median of 93.62. Over the past decade, Vericel's Days Sales Outstanding has ranged from 83.81 to 100.96. According to the industry distribution chart, Vericel ranks #506 out of 840 companies in the Biotechnology industry, placing it in the top 60.2%.
Is Vericel's Days Sales Outstanding too high?
Vericel's current Days Sales Outstanding of 87.23 is near median its 10-year median of 93.62. Over the past 10 years, this metric has ranged from a low of 83.81 to a high of 100.96. The Biotechnology industry median Days Sales Outstanding is 69.09. Vericel's value of 87.23 is 26.3% above this industry median. Based on the distribution chart, Vericel ranks #506 out of 840 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vericel has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Days Sales Outstanding compare to KLRA and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #506 out of 840 companies for Days Sales Outstanding. This places Vericel in the lower half of its industry. The industry median Days Sales Outstanding is 69.09. Vericel's value of 87.23 is 26.3% above this benchmark. Historically, Vericel's own Days Sales Outstanding has ranged from 83.81 to 100.96 over the past decade. While the company's 10-year median is 93.62 vs. the industry median of 69.09, Vericel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.09, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vericel's current Days Sales Outstanding of 87.23 is 26.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vericel and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vericel's current Days Sales Outstanding is 87.23, which is near median its own 10-year median of 93.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $53.77, compared to a current price of $44.30 — trading 17.6% below its estimated fair value. The current Days Sales Outstanding is 87.23, which is near median its 10-year median of 93.62 and 26.3% above the Biotechnology industry median of 69.09. Vericel's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Vericel (VCEL), the current Days Sales Outstanding is 87.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $44.30 is trading 17.6% below its estimated GF Value™ of $53.77.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
Days Sales Outstanding: 87.23 (near median its 10-year median of 93.62)
GF Value™: $53.77 vs. price of $44.30 (17.6% below fair value)
Industry Position: 26.3% above the Biotechnology median (#506 of 840)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
83GF Score
Get the complete analysis for VCEL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
